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Exposure to naturally occurring variants of herpesviruses in clinical settings can have a dramatic impact on
anti-viral immunity. Here we have evaluated the molecular imprint of variant peptide-MHC complexes on
the T-cell repertoire during human cytomegalovirus (CMV) infection and demonstrate that primary
co-infection with genetic variants of CMV was coincident with development of strain-specific T-cell
immunity followed by emergence of cross-reactive virus-specific T-cells. Cross-reactive CMV-specific T
cells exhibited a highly conserved public T cell repertoire, while T cells directed towards specific genetic
variants displayed oligoclonal repertoires, unique to each individual. T cell recognition foot–print and
pMHC-I structural analyses revealed that the cross-reactive T cells accommodate alterations in the pMHC
complex with a broader foot-print focussing on the core of the peptide epitope. These findings provide novel
molecular insight into how infection with naturally occurring genetic variants of persistent human
herpesviruses imprints on the evolution of the anti-viral T-cell repertoire.
I
nfection with human cytomegalovirus (CMV) is the most common cause of infectious complications in
newborns, causing deafness and other developmental abnormalities1,2. CMV also leads to serious complica-
tions in patients actively undergoing immunosuppression following both solid organ and hematopoietic stem
cell transplantation3. Whilst pre-existing immunity in both settings plays a central role in reducing disease
burden, intrauterine transmission of CMV and subsequent hearing loss in infants has been reported fromwomen
with pre-conceptional immunity4-7. It is now well established that exposure to heterologous strains of CMV in
immunocompetent individuals can alter the humoral response to CMV, leading to the emergence of new non-
crossreactive neutralizing antibodies recognising surface glycoproteins8. In a solid organ transplant setting, donor
seropositivity increases the risk of CMV antigenemia, even in seropositive recipients9. Recent genotypic analysis
has revealed the complex nature of CMV infection in transplant recipients, whereby the presence of multiple
genotypically distinct CMV strains has been observed and the presence of multiple genotypes has been associated
with increased viral load and delayed viral clearance10,11.
Despite emerging evidence that exposure to genotypically distant variants of CMV is a common phenomenon
that can lead to CMV-associated disease, little is known about the potential impact of exposure to genetic variants
of CMVon the T cell repertoire in humans. Therefore to explore this we analysed the impact of sequence variation
within the immunodominant immediate-early (IE) 1 protein of CMVon the T cell response. Using a combination
of functional avidity analysis, major histocompatibility complex (MHC) multimer staining, T cell repertoire
analysis, biophysical and structural analysis, we provide insight into the complex dynamics of the T cell repertoire
generated in response to heterologous strains of CMV. We demonstrate that exposure to heterologous strains of
OPEN
SUBJECT AREAS:
IMMUNOLOGICAL
MEMORY
VIRAL INFECTION
Received
2 December 2013
Accepted
20 January 2014
Published
10 February 2014
Correspondence and
requests for materials
should be addressed to
C.S. (corey.smith@
qimr.edu.au)
SCIENTIFIC REPORTS | 4 : 3993 | DOI: 10.1038/srep03993 1
CMV shapes the peripheral blood T cell repertoire, which is reflected
in both the functional profile of virus-specific T cells and the bio-
physical interactions between peptide-MHC (pMHC) and pMHC-T
cell antigen receptor (TCR).
Results
Longitudinal evolution of anti-viral CD81T cell responses follow-
ing primary co-infection with genetic variants of CMV. Previous
studies have shown that exposure to genetic variants of human
herpesviruses in persistently infected individuals can impact on the
selection of the anti-viral T cell repertoire12,13. However, very little is
known on how these T cell responses evolve following primary infec-
tion with distinct genetic variants and their impact on the establish-
ment of memory/effector anti-viral T cell repertoire. To address this
issue we focused on an immunodominant HLA B8-restricted IE-1
epitope for which four distinct genetic variants have been
identified14,15. These include ELRRKMMYM (referred to as ELR_
MYM), ELKRKMIYM (referred to as ELK_IYM), ELKRKMMYM
(referred to as ELK_MYM) and ELNRKMIYM (referred to as
ELN_IYM)14,15. These epitope variants contain a conserved
mutation (R R K) or a non-conserved (R R N) mutation at
position 3, a known HLA B8 anchor residue16, and a mutation at
position 7 (M R I). We initially investigated the impact of co-
infection with CMV genetic variants in a seronegative HLA B81
transplant recipient who received a kidney transplant from a
seropositive donor. This transplant recipient developed acute
primary CMV infection six months after transplant and continued
to show recurrent viral reactivation for a prolonged period. Sequence
analysis of viral DNA from the peripheral blood revealed that this
patient was co-infected with two distinct genetic variants of CMV
encoding HLA B8-restricted IE-1 epitopes ELR_MYM and ELK_
IYM. To assess the impact of these genetic variants on anti-viral T
cell immunity, we first co-stained peripheral blood CD81 T cells with
pMHC multimers specific for ELR_MYM and ELK_IYM epitopes.
These analyses revealed that this patient generated two distinct T cell
populations recognizing the ELR_MYM or ELK_IYM epitopes simul-
taneously around sixteen months post-transplant (Fig. 1a). The
frequency of these T cells progressively increased with ELR_MYM-
specific T cells dominating overall expansion. Interestingly, analysis of
CMV-specific CD81 T cells at 54 months post-transplant showed the
emergence of a cross-reactive T cell population, which recognized
both ELR_MYM and ELK_IYM, suggestive of the evolution of a
cross-reactive T cell population over time (Fig. 1a).
To further characterize the broader reactivity of CMV-specific
CD81 T cells against other IE-1 genetic variants, we conducted ex
vivo intracellular cytokine assays using ELR_MYM, ELK_IYM,
ELK_MYM and ELN_IYM synthetic peptides. Consistent with the
data obtained with pMHC multimers, a gradual predominance of
ELR_MYM-specific T cells early post-reactivation was observed
(Fig. 1b). More importantly, the broader cross-recognition by IE-1
specific T cells not only extended to the ELK_IYM epitope but also
ELK_MYMand ELN_IYM as well.We next expanded CMV-specific
CD81 T cells in vitro using ELR_MYM and ELK_IYM peptide epi-
topes and assessed their reactivity against four different genetic var-
iants of the IE-1 epitope. Data presented in Figure 1c shows that the T
cells expandedwith ELK_IYMpeptide showed broad cross-reactivity
against ELR_MYM, ELK_IYM, ELK_MYM and ELN_IYM epitopes,
while stimulation with ELR_MYM peptide generated T cells which
only recognized ELR_MYM and ELK_MYM epitopes. Taken
together these preliminary analyses suggested that primary exposure
to distinct genetic variants of CMV can have a significant impact on
the evolution of T cell responses and their ability to recognize variant
epitope sequences.
Ex vivo profiling of IE-1-specific T cells from individuals infected
naturally occurring genetic variants of CMV. To extend our
preliminary analyses described above, we recruited a cohort of 18
HLA B81 individuals including eight solid organ transplant
recipients and ten healthy virus carriers. Five transplant recipients
were seropositive before engraftment, while three patients under-
went primary infection following transplant from seropositive
donors. Ex vivo analysis using the dual MHC-multimer staining
revealed four distinct patterns of pMHC multimer staining.
Representative analyses of these distinct patterns of staining are
shown in Figure 2a. In both transplant recipients and healthy
individuals, the majority of individuals showed preferential
binding of either ELR_MYM (represented by Tx4 and H6) or
ELK_IYM (represented by Tx7 and H4) multimers. Interestingly,
some individuals cross-recognized both ELR_MYM and ELK_IYM
variants (represented by Tx2 and H1), while others (represented by
Tx9 and H5) bound the pMHC multimers independently of each
other, similar to that seen in the transplant patient in Figure 1.
To further profile the T cell cross-recognition of distinct genetic
variants, we next performed ex vivo intracellular IFN-c assays using
ELR_MYM, ELK_IYM, ELK_MYM and ELN_IYM peptides.
Representative data from five transplant recipients and five healthy
virus carriers is shown in Figure 2b. While consistent with the dual
MHC-multimer analysis, these observations revealed distinct pat-
terns of recognition that were differentially influenced by the amino
acid substitutions at positions 3 and 7. Individuals whose T cells
cross-recognised both of the MHC-multimers (Tx2 and H1)
responded efficiently to the ELR_MYM, ELK_IYM, and ELK_
MYM variants, but failed to recognise the ELN_IYM, suggesting that
while their T cells could accommodate the conserved RRKmutation
at position 3, and the MR I mutation at position 7, they could not
accommodate the RRNmutation at position 3.Whereas individuals
displaying differential binding of the multimers could only accom-
modate the amino acid substitution at position 3, whereby reactivity
to the ELK_MYM variant was evident in donors who preferential
bound the ELR_MYM multimer (Tx4, Tx9, H5 and H6), and react-
ivity to the ELN_IYM variant was also evident in donors who recog-
nised ELK_IYM (Tx7, Tx9, H4 and H5). Interestingly, one
individual, H8, preferentially recognised the ELN_IYM variant, with
reduced reactivity to the ELK_IYM variant.
To confirm the preferential recognition of different variants by
individual donors we expanded T cells specific for the ELR_MYM,
ELK_IYM or ELN_IYM epitopes following in vitro stimulation with
cognate peptide, and tested these T cells for recognition of all four
variant peptides. Representative analysis from eight populations is
shown in Figure 3. Consistent with our ex vivo analysis T cells from
individuals that cross-recognised the ELR_MYM, ELK_IYM and
ELK_MYM variants could be expanded from some individuals
(represented by H1). Conversely T cells from other donors, who
did not efficiently cross-recognise both multimers, displayed pref-
erential recognition of either ELR_MYM and ELK_MYM (Tx9, H5
and H6), following expansion with ELR_MYM, ELK_IYM following
expansion with ELK_IYM (Tx9, H5 and H4), or ELN_IYM (H8).
These observations also confirmed that in some donors (Tx9 and
H5) co-infection with genetic variants can lead to distinct variant
specific non-cross reactive T cell populations.
We next sought to explore the ability of the different IE-1 specific T
cell populations to recognise the endogenously processed epitope var-
iants in a viral infection setting. HLA B81 fibroblasts were infected
with either the TB40E or Merlin strains of CMV, which encode the
ELK_IYM and ELR_MYM variants, respectively. IE-1 specific T cells
from 4 donors: 1 cross-reactive (H1), 1 ELR_MYM specific (Tx9) and
2 ELK_IYM specific (Tx9 and H4), were then incubated with the
infected fibroblasts and assessed for IFN-c production (Fig 4).
Although the cross-reactive T cells were capable of recognising both
the Merlin and TB40E strains, these effector cells displayed reduced
recognition of the ELR_MYM expressing Merlin strain-infected cells
(Fig. 4a). This reduced recognition of endogenously processed
www.nature.com/scientificreports
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ELR_MYM variant epitope was not due to poor infectivity, since
target cells infected with the Merlin strain were efficiently recognized
by ELR_MYM-specific T cells from Tx9 (Fig. 4b). The ELR_MYM
and ELK_IYM-specific T cells displayed exquisite specificity for cog-
nate variant epitope and only recognised either Merlin or TB40E
infected cells, respectively (Fig. 4b-d).
Clonotypic analysis of the TCR repertoire for CD81 T-cells specific
for different variants of IE-1 epitopes. To examine the impact of
exposure to naturally occurring CMV genetic variants on the TCR
repertoire architecture of the virus-specific CD81 T-cells, we
employed a novel protocol which allows single-cell paired analysis
of TRAV and TRBV sequences17. To compare the TCR repertoire in T
cells displaying different levels of cross-reactivity, we enriched CD81
T cells which bound to both ELR_MYM-HLA B8 and ELK_IYM-
HLA B8 multimers and compared the TCR architecture to T cells
which bound specifically to ELR_MYM-HLA B8, ELK_IYM-HLA B8
or the ELN_IYM-HLA B8multimers. These enriched antigen-specific
CD81 T cells were then analysed for TRAV and TRBV usage. TCR
CDR3 usage confirmed the unique nature of the T cell repertoires
generated in response to the different epitope variants (Table 1).
CMV-specific clonotypes which cross-recognized the ELR_MYM
and ELK_IYM epitopes showed a high level of conservation at the
nucleotide level, which has been described as a ‘Type 3 bias’, whereby
both the TRBV usage and CDR3 sequence was identical. Further-
more, when the CDR3 region from the TRAV chain was sequenced,
Figure 1 | The kinetics of variant specific T cell activation following viral reactivation in a seronegative transplant recipient. (a) PBMC from a
transplant patient (Tx1) at different stages post-transplant were co-stained with a PE-conjugated HLA B8/ELK_IYM dextramer and an APC conjugated
HLA B8/ELR_MYMdextramer, then labeled with anti-CD8. (b) PBMC from Tx1 were incubated for five hours with the HLA B8-restricted IE-1 encoded
peptide epitope variants, labeled with anti-CD8 and then assessed for intracellular expression of IFN-c. Data shows the percentage of IFN-c producing
CD81 T cells reactive against each of the epitope variants. (c) Following in vitro expansion for two weeks in the presence of cognate peptide and IL-2,
ELR_MYM or ELK_IYM specific T cells were incubated for four hours with all four peptide variants, then IFN-c expression was assessed using an
intracellular cytokine assay. FACS plots show the proportion of ELR_MYM or ELK_IYM expanded CD81 T cells responding to the peptide epitope
variants.
www.nature.com/scientificreports
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it too showed high levels of bias. These observations were confirmed
following TRBV analysis in other individuals who generated a cross-
reactive T cell response. Conversely, CD81 T cells recognizing
ELK_MYM or ELK_IYM showed oligoclonal TCR architecture with
a clear bias in CDR3 usage with a single dominant clonotype in each
individual representing 45-80% of CDR3 sequences. Of note, one
minor clonotype (TRBV5-6/TRAV19) was detected in both the
ELK_IYM and ELR_MYM multimer populations sorted from one
individual who showed evidence of distinct ELR_MYM and
ELK_IYM specific T cell populations, suggesting the presence of a
small cross-reactive clonotype in this individual. Type-I TCR
bias18,19 was observed in the ELR_MYM response with two separate
individuals deploying T cells bearing TRBV27 and TRAV19 TCR
architecture. Analysis of T cells directed towards the ELN_IYM
variant epitope also showed an oligoclonal TCR repertoire with
distinct TRAV and TRBV usage when compared to the T cells that
recognized both ELR_MYM and ELK_IYM epitopes. These
observations indicate that virus-specific T cells with broader cross-
reactivity display highly-biased monoclonal TCR repertoire, while
effector cells directed towards specific genetic variants displayed an
oligoclonal repertoire which was uniquely altered in each virus-
infected individual.
TCR interaction with HLA B8-ELR_MYM and HLA B8-ELK_IYM
complexes. To gain further insight into TCR recognition of these
variant epitopes, single amino acid substitutions were introduced
into the ELR_MYM and ELK_IYM peptides and the analogue
peptides were tested for T cell recognition by three different IE-
specific T cell lines. These T cells either cross-recognized both ELR_
MYM and ELK_IYM peptides or reacted exclusively against the
ELR_MYM or ELK_IYM peptides. The T cells which cross-
recognized both ELR_MYM and ELK_IYM peptides displayed a
broad footprint on the MHC-bound peptide as replacement of any
residue from P3-P8 with alanine dramatically impacted on immune
Figure 2 | Recognition of IE-1 peptide variants by HLA B8 transplant recipients and healthy volunteers. (a) PBMC from HLA B8 CMV-seropositive
individuals were co-stained with a PE-conjugated HLA B8/ELK_IYM dextramer and an APC conjugated HLA B8/ELR_MYM dextramer, then labeled
with anti-CD8. The frequency of MHC multimer positive CD81 T cells from individuals displaying the four distinct patterns of dextramer binding is
shown. (b) PBMC from HLA B8-positive transplant recipients and healthy volunteers were incubated for five hours with the HLA B8-restricted IE-1
encoded peptide epitope variants, labeled with anti-CD8 and then assessed for intracellular expression of IFN-c. Data shows the percentage of IFN-c
producing CD81 T cells reactive against each of the epitope variants in a total of 5 transplant recipients and 5 healthy volunteers.
www.nature.com/scientificreports
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recognition (Fig. 5). In contrast, T cells exclusively recognizing the
ELR_MYM or ELK_IYM epitopes showed greater flexibility as
residues P1, P2, P3, P9, and/or P5 and P7 could be replaced with
alanine with minimal impact on the immune recognition. It is
important to note that although the P7 residue was crucial for the
immune recognition by ELK_IYM-specific T cells, substitution of this
residue with alanine had minimal impact on the immune recognition
by ELR-MYM-specific T cells (Fig. 5).
Structural characterization of HLA B8-ELR_MYM, HLA B8-
ELK_IYM and HLA B8-ELN_IYM complexes. Considering the
impact of pMHC structural constraints on the binding of the TCR
and its selection within an immune repertoire, we next determined
whether the structural landscape of the HLA B8-ELR_MYM, HLA
B8-ELK_IYM and HLA B8-ELN_IYM complexes correlated with
the pattern of T cell recognition. Thermal stability (Tm) analysis of
the HLA B8-ELR_MYM, HLA B8-ELK_IYM and HLA B8-ELN_
IYM complexes revealed that the ELR_MYM (Tm: 63.061.0uC)
and ELK_IYM (Tm: 63.26 0.8uC) peptides bound the HLA B8
molecules with more stability when compared to the ELN_IYM
peptide (Tm: 58.260.8uC). Crystal structures of the HLA B8-
ELR_MYM, HLA B8-ELK_IYM and HLA B8-ELN_IYM revealed
that although the N-terminus of the three peptides adopted a
similar conformation in the peptide-binding cleft of HLA B8,
important differences were observed in the interaction of other
peptide residues with the HLA molecule (Fig. 6a). Of particular
interest was the P3 residue, which acts as an anchor residue for
HLA B8-binding peptides16. Namely, the P3-Arg side chain of the
ELR_MYMpeptide pointed into the antigen binding cleft ofHLAB8,
and was stabilized by salt bridges and hydrogen bonds to Asp156,
Asp114 and Tyr116 (Fig. 6b). However, the shorter side chains of the
Lys and Asn, in the ELK_IYM and ELN_IYM peptides respectively,
failed to contact Tyr116 (Fig. 6B). In the ELK_IYM-HLA B8
structure, Tyr116 shifted its hydroxyl group by 1.7 A˚ compared to
the ELR_MYM structure. Whereas in the ELN_IYM-HLA B8
structure, we observed multiple discrete conformations of Tyr116,
one of which interacted with the P5-Lys (Fig. 6b). The conformation
of the solvent exposed residues P6, P7 & P8, which are likely
Figure 3 | Recognition of epitope variants following in vitro expansion. Following in vitro expansion for two weeks in the presence of cognate peptide
and IL-2, ELR_MYM ELK_IYM and ELN_IYM specific T cells were incubated for four hours with all four peptide variants, then IFN-c expression
was assessed using an intracellular cytokine assay. Data represents the proportion of CD81 T cells responding to the peptide epitope variants.
Figure 4 | Recognition of endogenously expressed variant epitopes. ELR_MYM/ELK_IYM (a), ELR_MYM (b) or ELK_IYM (c & d) specific T cells were
incubated for five hours with HLA B81 fibroblasts infected with the ELR_MYM encoding Merlin or ELK_IYM encoding TB40E strains. IFN-c
expression was then assessed using an intracellular cytokine assay. Data represents the proportion of ELR_MYM or ELK_IYM specific CD81 T cells
recognising the CMV-infected cells at the indicated responder to stimulator ratio.
www.nature.com/scientificreports
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important for TCR interaction20 were also altered. Namely, in the
ELK_IYM-HLA B8 and ELN_IYM-HLA B8 structures, the P6-Met
was positioned in the middle of the groove, making contact with
Thr69 and Thr73, whereas the P6-Met in the ELR_MYM structure
leant towards the a2-helix, making contact with residues Ala150,
Arg151 and Val152 (Fig. 7a). These collective structural differences
impacted on the Ag-binding cleft and hence potential TCR contact
surface. Namely, themovement of P6-Met in the ELR_MYMpeptide
was accompanied by a shift in Tyr116 and Trp147, which resulted in
a more ‘‘open’’ antigen binding cleft (a displacement of the a1-helix
by 0.5 A˚ compared to the respective Ag-binding clefts of the
ELK_IYM and ELN_IYM structures) (Fig. 7a). The P7-Met side
chain of the ELR_MYM peptide contacts the P8-Tyr side chain
(Fig. 7b), which adds a structural constraint and influences the
Table 1 | TCR usage of IE-1 variant specific T cell populations
Specificity Donor TRAV CDR3 TRAJ TRBV CDR3 TRBJ TRBD TRBV Freq.
ELR_MYM/ELK_IYM H1 19*01 CALGANFGNEKLTF 48*01 27*01 CASSQGLAGLEETQYF 2-5*01 2*01 35/35
H7 No Data 27*01 CASSQGLAGLQETQYF 2-5*01 2*01 9/9
H9 No Data 27*01 CASSLGLAGLTDTQYF 2-5*03 2*01 10/10
ELK_IYM H2 38-2 CAFGGSQGNLIF 42*01 2 CASSFGLSSYNSPLHF 1-6*02 2*01 15/21
38-2 CAFGGSQGNLIF 42*01 12-3 CASGLTHVPQHF 1-5*01 2*01 1/21
38-2 CAYRSGNFNKFYF 21*01 6-4 CASSSRDTLGEYTEAFF 1-1*01 1*01 2/21
21 CAVYNNNDMRF 43*01 6-4 CASSSRDTLGEYTEAFF 1-1*01 1*01 1/21
13-2 CAVPPGASGTYKYIF 40*01 29-01 CSVEGGTIYEQYF 2-7*01 2*01 1/21
No Data 19*01 CASRGGPQETQYF 2-5*01 1*01 1/21
H5 27*01 CAGAEGAAGNKLTF 17*01 7 CASSSPGLAGAQEYF 2-7*-01 2*01 24/30
24*01 CAFIGYSGYALNF 31 30 CAWRETDNYGYTF 1-2*01 1*01 3/30
12-2 CAVNRYGNKLVF 47*02 20-1 CSARDENQGAEAFF 1-1*01 1*01 1/30
1-2*01 CAVYSSGGANNLFF 36*01 10-3 CAIRTGQANEQYF 2-7*01 1*01 1/30
19*01 CAPNARLMF 31*01 5-6 CASTLGGYAGNTIYF 1-3*01 2*01 1/30
ELR_MYM H10 20*01 CAVQGTGGFKTIF 9*01 7 CASSLDVGQYLGNEQFF 2-1*01 1*01 8/12
19*01 CAPNARLMF 31*01 5-6 CASTLGGYAGNTIYF 1-3*01 2*01 2/12
8-1*01 CAVLGAGNMLTF 39*01 19 CASSMAAPFPFDGYTF 1-2*01 2*01 1/12
13-2 CAEVAEKSSGDKLTF 46*01 27*01 CASSSYRVSLNTEAFF 1-1*01 1*01 1/12
H5 38-1 CAFRGAGNMLTF 39*01 2 CASIPWQGANGEQYF 2-7*01 2*01 14/24
19*01 CAQGSNFGNEKLTF 48*01 27*01 CASSSYRTNLNTEAFF 1-1*01 1*01 9/24
5*01 CAETQPGAGSYQLTF 28*01 27*01 CASSLGPGQEQYF 2-7*01 1*01 1/24
ELN_IYM H8 12-3 CAGAEGAAGNKLTF 50*01 20-1 CSAKSRDRTGANVLTF 2-6*01 1*02 5/11
14 CAETQPGAGSYQLTF 28*01 29-1 CSVVGGQSYEQYF 2-7*01 2*01 5/11
25*01 CAIYGGSQGNLIF 42*01 20-1 CSANEGIHYGYTF 1-2*01 2*02 1/11
Figure 5 | Recognition of alanine analogs by ELR_MYM and ELK_IYM-specific T cells. ELR_MYM and ELK_IYM specific T cells were incubated for
five hours with both wild-type peptide and alanine analogs of ELR_MYM and ELK_IYM peptides, then assessed for intracellular IFN-c expression.
Data presented in each of the subpanels show relative IFN-c expression in the presence of alanine analogs compared with the wild-type peptide.
www.nature.com/scientificreports
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overall shape of the peptide, as seen previously in other MHC
molecules21. This interaction turns the P8-Tyr side-chain 180u
towards the a1-helix in comparison to the ELK_IYM and
ELN_IYM peptides structures. It is also important to note that
although the P7 residue was crucial for the immune recognition by
ELK_IYM-specific T cells, substitution of this residue with alanine
had minimal impact on the immune recognition by ELR-MYM-
specific T cells (Fig. 5). This contrasting pattern of T cell
recognition was supported by the structural analysis which clearly
showed that the P7 residue side chain of the ELR_MYM peptide
contacts the P8 residue side chain and thus turns this residue 180u
towards the a1-helix. This positioning may reduce the interaction of
the P7 residue with the TCR for ELR_MYM-specific T cells, while
TCR recognizing ELK_IYM epitope can interact with both P7 and P8
residues.
Discussion
TheCD81 T cell response generated following infection with CMV is
directed towards a diverse array of antigens and plays a crucial role in
preventing the establishment of chronic symptomatic disease15,22-25.
This is particularly evident in the transplant setting, whereby seros-
tatus of both the donor and recipient have a significant impact
upon viral infection9. However, it has become increasing evident
from studies investigating the presence of genotypically distinct
strains of CMV in the transplant setting that although pre-existing
immunity is protective against disease it may not necessarily prevent
re-infection9-11. Observations from immunocompetent individuals
have also shown that serial re-infection is likely to occur and that
exposure to heterologous strains of CMV can alter the subtype spe-
cific antibody response8,26. Despite this little is known about the
impact exposure to heterologous strains of virus has upon the T cell
response. Whilst previous studies have investigated the impact of IE-
1 sequence variation on T cell recognition27,28, the present study
delineates how infection with genotypic variants of CMV imprints
on the T cell repertoire in exposed individuals.
The parallel emergence of multiple strains encoding the
ELR_MYM and ELK_IYM epitope variants in a transplant recipient,
and the detection of variant specific T cell populations in other
Figure 6 | The structure of the HLA B8molecule in complex with the IE-1 epitope variants. (a) The panels show a cartoon representation of the HLA B8
molecule with the peptide in stick colour in blue for the ELR_MYM peptide, in green for the ELK_IYM peptide, and pink for the ELN_IYM peptide.
(b) The panels show the specific interaction (residue shown in stick) of the peptide P3 and P5 residues with the antigen binding cleft of the HLA B8
molecule. The peptides were coloured according to panel A, and the red dashed lines represent hydrogen bond interactions.
www.nature.com/scientificreports
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individuals supports previous observations that simultaneous infec-
tion with CMV can occur, even in healthy individuals10,29, and
implies that strain specific immunity may play a role in the control
viral reactivation, at least in settings of co-infection following organ
transplantation. Interestingly, while previous observations have indi-
cated that T cell repertoires following CMV infection are relatively
stable during latent infection30, our observations suggest that co-
infection can alter the T cell repertoire and selectively promote the
expansion of clonotypes that can cross-react with multiple virus
strains. While it is not evident what impact the selection of a cross-
reactive clonotype over time has upon the control of reactivating
CMV variant viruses, recent evidence in HIV infected individuals
has demonstrated that the recruitment of cross-reactive clonotypes
recognising HIV variants plays an important role in long-term
immunity associated with elite controllers31,32.
The biophysical and structural landscape of the peptide-MHC
complex plays a critical role in TCR selection18,21,33-36.
Unsurprisingly, given the distinct nature with which the different
populations recognise variant peptides, we saw little evidence for
highly predictable public TCR usage in the IE-1 variant specific T
cell populations. However, these observations did reveal a bias in the
repertoire capable of efficiently recognising both immunodominant
variants with the selection of a single cross-reactive TCR. Structural
observations and alanine substitution of the ELR_MYM and
ELK_IYM variants further emphasised the likely influence TCR rep-
ertoire selection plays in defining the patterns of variant recognition.
The cross-reactive TCR was highly susceptible to alanine substi-
tution at position 3, which completely ablated T cell activation.
Although this T cell could accommodate the Arg to Lys substitution
at position 3, it could not accommodate the Arg to Asn substitution
that is found in the ELN_IYM variant, whereas the ELK_IYM spe-
cific T cells that appear to preferentially dock at the C-terminus of the
peptide could accommodate this substitution. The structural differ-
ences that restricted cross-recognition of the ELR_MYM/HLA B8
and ELK_IYM/HLA B8 complexes by the majority of the variant
specific T cells were primarily driven by the residue substitution at
position 7, and the impact this had upon residues 6 and 8. Similar
observations have previously demonstrated how intra-peptide inter-
actions, or peptide-induced conformational change can influence
TCR binding21,37-40. Less obvious were the mechanisms that dictate
differential recognition of the ELK_IYM and ELN_IYM peptide var-
iants which displayed a very similar structure. Previous studies using
the Human Immunodeficiency Virus encoded HLA B8 restricted
epitope, GGKKKYKL, and a variant, GGRKKYKL, suggested that
a shift in the position of the MHC a1 and a2 helices which flank the
peptide binding groove following substitution of the P3-K with the
larger arginine residue were responsible for the failure of
GGKKKYKL specific T cells to recognize the GGRKKYKL variant16.
Whilst substitution of K for R at P3 appeared to have no bearing on
the recognition of the IE-1 peptide variants, differential interaction of
the ELN_IYM and ELK_IYM peptides with the HLA B8 molecule
also likely alter TCR recognition. Position 3 is a known HLA B8
anchor residue, therefore the reduce thermostability of the
ELN_IYM HLA B8 complex is likely attributable to the less stable
interaction of the P3-Asn residue with the HLA B8 molecule. This
could also potentially alter the flexibility of the peptide in the MHC
groove. It has previously been reported that increased peptide flex-
ibility can alter the responding TCR repertoire33, although in this
instance instability was due to polymorphisms in theMHCmolecule
rather than the peptide itself.
Overall, these observations provide insight into the impact expo-
sure to heterologous strains of CMV has upon the T cell repertoire.
The collective results paint a complex and dynamic picture of the
interaction between CMV and the human T cell repertoire, dem-
onstrating the impact exposure to viral variants, co-infection with
multiple viral variants and TCR repertoire selection have upon the
induction of the cellular immune response to CMV.
Methods
Study Participants. A panel of 9 solid organ transplant recipients (SOT; renal or
heart and/or lung) and 10 HLA B8-positive human volunteers were recruited after
informed written consent in accordance with the Queensland Institute of Medical
Research ethical guidelines. This study was approved by the Human Ethics
Committees of the Queensland Institute of Medical Research, the Prince Charles
Hospital and the Princess Alexandra Hospital.
Figure 7 | Structural changes associated with the P6-P8 residues of the
IE-1 epitope variants in complex with the HLA B8 molecule. (a) The
panels represent a superposition of the three peptide-HLA B8 structures,
with the HLA B8 molecules represented in cartoon and the peptide
coloured in blue for ELR_MYM, in green for ELK_IYM and pink for
ELN_IYM. The spheres represent the Ca atom of the P6 residue on the
peptides and of the Ala150, Arg151, Val152, Thr69 and Thr73 on the HLA
B8 molecules. The blue dashed lines represent the atomic interaction
between the peptide residues and the HLA B8 residues. (b) The panel
shows the structural difference in the peptides at position P7 and P8, with
the peptides coloured according to panel A, and the blue dashed line
represents the interaction between the P7 and P8 residues of the
ELR_MYM peptide.
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Establishment and maintenance of cell lines. Polyclonal T cell lines specific for the
HLA B8-restricted CD81 T cell epitope variants from the IE-1 protein, ELR_MYM,
ELK_IYM and ELN_IYM, were generated following stimulation of PBMC with 1mg/
ml of cognate peptide. Polyclonal T cell cultures were maintained in growth medium
containing recombinant interleukin-2 (IL-2).
pMHC Dextramer staining. MHC-peptide dextramers supplied by Immudex were
used to detect epitope-specific CD81 T cells. For dual dextramer staining, PBMCs
were incubated for ten minutes at 4uC with both the APC labelled HLA B8/
ELR_MYM dextramer and the PE labelled HLA B8/ELK_IYM dextramer. Cells were
then washed and incubated for a further 30 minutes at 4uC with PerCP-Cy5.5 anti-
CD8, PE-Cy7 anti-CD3 (BD Biosciences), efluor450 anti-CD19 and Pacific Blue anti
CD14 (BD Biosciences). Cells were then acquired using a FACSCanto II with
FACSDiva software, and post-acquisition analysis performed using FlowJo software.
Intracellular Cytokine Staining. PBMC or peptide epitope stimulated bulk T cell
cultures were stimulated with either 1mg/mL of peptide or with IFN-c activated HLA-
matched fibroblasts infected with the HCMV strains TB40E or Merlin (kind gifts
from Dr Barry Slobedman, Westmead Millennium Institute, Sydney, Australia) to
assess endogenous antigen recognition. Cells were incubated for four to five hours in
the presence of Brefeldin A (BD Biosciences), then incubated with PerCP-Cy5.5 anti-
CD8 (eBioscience), fixed and permeabilised using a BD Cytofix/Cytoperm kit, and
incubated with PE or AF700 anti-IFN-c (BD Biosciences). Cell acquisition was
performed using a FACS Canto II (BD Biosciences). Post-acquisition analysis was
performed using FlowJo software (TreeStar).
TRAV and TRBV Sequence Analysis. Paired analysis of TRAV and TRBV CDR3
usage was performed using a recently described method involving multiplex analysis
in single cells17. Briefly, PBMC fromHLA B81 individuals were labelled with pMHC
dextramer, then dextramer positive T cells were single cell sorted into a 96 well plate
using a FACSAria (BDBiosciences). Nested multiplex PCR for TRAV and TRBV was
then performed on sorted single cells. PCR products were then sequenced and
analysed for TRAV and TRBV CDR3 usage using the IMGT/V-QUEST software41.
Thermostability assay. To assess the effect of each mutation, either on the HLA
molecule or on the peptide stability, a thermal shift assay was performed. The
fluorescent dye Sypro orange was used tomonitor the protein unfolding. The thermal
stability assay was performed in the Real Time Detection system (Corbett RotorGene
3000). Each pMHC complex in 10 mM Tris-HCl pH 8, 150 mM NaCl, at two
concentrations (5 and 10 mM) in duplicate, was heated from 25uC to 95uC with a
heating rate of 1uC/min. The fluorescence intensity was measured with excitation at
530 nm and emission at 555 nm. The Tm, or thermal melt point, represents the
temperature for which 50% of the protein is unfolded.
Protein expression, purification and crystallisation. Soluble class I heterodimers
containing the three CMV peptides (ELR_MYM, ELK_IYM and ELN_IYM) were
prepared as described previously42. Briefly, the truncated forms (residues 1–276) of
the HLA B8 heavy chain and full-length b2-microglobulin (b2m) were expressed in
Escherichia coli as inclusion bodies. The complex of HLA B8-peptides were refolded
by diluting the heavy chain and b2m inclusion body preparations into refolding
buffer containing a molar excess of peptide ligand. The refolded complexes were
concentrated and purified by anion exchange chromatography and gel filtration
chromatography. Crystals of the HLA B8 in complex with the three CMV peptides,
ELK_IYM, ELR_MYM and ELN_IYM were grown by the hanging-drop, vapour-
diffusionmethod at 20uCwith a protein/reservoir drop ratio of 1:1, at a concentration
of 10 mg/mL in 10 mM Tris-HCl pH 8, 150 mM NaCl. Large stick-shaped crystals
grew using 15-20% Poly Ethylene Glycol (PEG) 4000), 0.2 M ammonium acetate and
0.1 M Na-Citrate pH 5.6.
Data collection and structure determination. The HLA B8-peptide crystals were
soaked in a cryoprotectant solution containing mother liquor solution with the PEG
concentration increased to 30%(w/v) and then flash frozen in liquid nitrogen. The
data were collected on the MX1 beamline for the HLA B8-ELR_MYM, and on the
MX2 beamline for the HLA B8-ELK_IYM and HLA B8-ELN_IYM complexes,
at the Australian Synchrotron, Clayton using the ADSC-Quantum 210 and 315r CCD
detectors respectively (at 100K). Data were processed using the XDS software and
scaled using XSCALE software43. The HLA B8-peptide crystals belonged to the space
group P212121 with unit cell dimensions (Supplemental Table 1) consistent with one
complex in the asymmetric unit. The structures were determined by molecular
replacement using the PHASER program44 with the HLA B8-FLR for the HLAmodel
without the peptide (Protein Data Bank accession number, 1M05)42. Manual model
building was conducted using Coot software45 followed by maximum-likelihood
refinement with the PHENIXprogram46. Coordinates submitted to the PDBdatabase,
pdb codes (to be advised): for the HLA B8-ELK_IYM, HLA B8-ELR_MYM and HLA
B8-ELN_IYM complexes. All molecular graphics representations were created using
PyMol.
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